Mechanisms of Disease: Multiple endocrine neoplasia type 1 - Relation to chromatin modifications and transcription regulation

Nature Clinical Practice Endocrinology and Metabolism

Volumn 2, Issue 10, 2006, Pages 562-570

  Dreijerink, Koen M A ^a   Höppener, Jo W M ^a   Timmers, H T Marc ^a   Lips, Cornelis J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Gene transcription; Histone modification; Menin; Multiple endocrine neoplasia type 1 (MEN1); Tumorigenesis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2C; ESTROGEN RECEPTOR; HISTONE; HISTONE DEACETYLASE; HISTONE METHYLTRANSFERASE; LYSINE; NUCLEAR PROTEIN; ONCOPROTEIN; PARATHYROID HORMONE; PROLACTIN; PROTEIN; PROTEIN MENIN; PROTEIN P18; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUND; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADRENAL TUMOR; CANCER DIAGNOSIS; CANCER GENETICS; CARCINOGENESIS; CARCINOID; CLINICAL FEATURE; FAMILIAL CANCER; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPOPHYSIS TUMOR; MEN1 GENE; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL TUMOR; PARATHYROID TUMOR; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; TFF1 GENE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL NUCLEOLUS; CHROMATIN; GENE EXPRESSION REGULATION; GENES, JUN; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MODELS, BIOLOGICAL; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NF-KAPPA B; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 33749565775     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0292     Document Type: Review

References (50)

1. Brandi ML et al. (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86: 5658-5671
2. Chandrasekharappa SC et al. (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276: 404-407
3. Thompson NW (1998) Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 243: 495-500
4. Geerdink EA et al. (2003) Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? Eur J Endocrinol 149: 577-582
5. Roijers JF et al. (2000) Criteria for mutation analysis in MEN 1-suspected patients: MEN 1 case-finding. Eur J Clin Invest 30: 487-492
6. Burgess JR et al. (1999) Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch Surg 134: 1119-1123
7. Larsson C et al. (1988) Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332: 85-87
8. Heppner C et al. (1997) Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet 16: 375-378
9. Zhuang Z et al. (1997) Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 57: 4682-4686
10. Crabtree JS et al. (2001) A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 98: 1118-1123
11. Kouvaraki MA et al. (2002) Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg 137: 641-647
12. Wautot V et al. (2002) Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum Mutat 20: 35-47
13. Pannett AA et al. (2003) Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathyroidism. Clin Endocrinol (Oxf) 58: 639-646
14. Olufemi SE et al. (1998) Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1 Burin) in four kindreds from Newfoundland. Hum Mutat 11: 264-269
15. Guru SC et al. (1998) Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci USA 95: 1630-1634
16. Chandrasekharappa SC and Teh BT (2003) Functional studies of the MEN1 gene. J Intern Med 253: 606-615
17. Schnepp RW et al. (2004) Functional interaction between tumor suppressor menin and activator of S-phase kinase. Cancer Res 64: 6791-6796
18. Ohkura N et al. (2001) Menin, a gene product responsible for multiple endocrine neoplasia type 1, interacts with the putative tumor metastasis suppressor nm23. Biochem Biophys Res Commun 282: 1206-1210
19. Jin S et al. (2003) Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res 63: 4204-4210
20. Sukhodolets KE et al. (2003) The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene. Mol Cell Biol 23: 493-509
21. Lopez-Egido J et al. (2002) Menin's interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity. Exp Cell Res 278: 175-183
22. Obungu VH et al. (2003) Menin, a tumor suppressor, associates with nonmuscle myosin II-A heavy chain. Oncogene 22: 6347-6358
23. Agarwal SK et al. (1999) Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96: 143-152
24. Heppner C et al. (2001) The tumor suppressor protein menin interacts with NF-κB proteins and inhibits NF-κB-mediated transactivation. Oncogene 20: 4917-4925
25. Kaji H et al. (2001) Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type β signaling. Proc Natl Acad Sci USA 98: 3837-3842
26. Lemmens IH et al. (2001) Menin interacts directly with the homeobox-containing protein Pem. Biochem Biophys Res Commun 286: 426-431
27. Kim H et al. (2003) Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res 63: 6135-6139
28. Hughes CM et al. (2004) Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell 13: 587-597
29. Yokoyama A et al. (2004) Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 24: 5639-5649
30. Yazgan O and Pfarr CM (2001) Differential binding of the Menin tumor suppressor protein to JunD isoforms. Cancer Res 61: 916-920
31. Gobl AE et al. (1999) Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism. Biochim Biophys Acta 1447: 51-56
32. Gallo A et al. (2002) Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation. Oncogene 21: 6434-6445
33. Agarwal SK et al. (2003) Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci USA 100: 10770-10775
34. Blasco MA (2005) Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 6: 611-622
35. Lin SY and Elledge SJ (2003) Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113: 881-889
36. Sowa H et al. (2004) Menin inactivation leads to loss of transforming growth factor β inhibition of parathyroid cell proliferation and parathyroid hormone secretion. Cancer Res 64: 2222-2228
37. Lacerte A et al. (2004) Activin inhibits pituitary prolactin expression and cell growth through Smads, Pit-1 and menin. Mol Endocrinol 18: 1558-1569
38. Santos-Rosa H et al. (2002) Active genes are trimethylated at K4 of histone H3. Nature 419: 407-411
39. Guenther MG et al. (2005) Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci USA 102: 8603-8608
40. Yokoyama A et al. (2005) The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123: 207-218
41. Franklin DS et al. (2000) Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 20: 6147-6158
42. Milne TA et al. (2005) Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci USA 102: 749-754
43. Karnik SK et al. (2005) Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci USA 102: 14659-14664
44. Dreijerink KM et al. (2006) Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res 66: 4929-4935
45. La P et al. (2004) Direct binding of DNA by tumor suppressor menin. J Biol Chem 279: 49045-49054
46. Fraga MF et al. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391-400
47. Seligson DB et al. (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435: 1262-1266
48. Yaguchi H et al. (2004) Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Mol Cell Biol 24: 6569-6580
49. Busygina V et al. (2004) Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. Hum Mol Genet 13: 2399-2408
50. Asgharian B et al. (2004) Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin Cancer Res 10: 869-880